First human senolytic trials (2019)
Mayo Clinic researchers gave intermittent dasatinib plus quercetin to patients with idiopathic pulmonary fibrosis and diabetic kidney disease — the first human tests of drugs that clear senescent cells. The pair had been chosen for its track record killing senescent cells in mice.
Both small studies showed the regimen was tolerable and reduced senescent cell burden in tissue.
They established the intermittent dosing schedule and safety profile used in nearly every senolytic trial since.
The Amsterdam MASH trial uses the same drugs, dose schedule, and rationale, but tests a harder endpoint: histologic reversal of liver fibrosis.
